JP2024544393A5 - - Google Patents

Info

Publication number
JP2024544393A5
JP2024544393A5 JP2024535940A JP2024535940A JP2024544393A5 JP 2024544393 A5 JP2024544393 A5 JP 2024544393A5 JP 2024535940 A JP2024535940 A JP 2024535940A JP 2024535940 A JP2024535940 A JP 2024535940A JP 2024544393 A5 JP2024544393 A5 JP 2024544393A5
Authority
JP
Japan
Prior art keywords
approximately
ophthalmic composition
pharmaceutical ophthalmic
naoh
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024535940A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024544393A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/081775 external-priority patent/WO2023114986A1/en
Publication of JP2024544393A publication Critical patent/JP2024544393A/ja
Publication of JP2024544393A5 publication Critical patent/JP2024544393A5/ja
Pending legal-status Critical Current

Links

JP2024535940A 2021-12-17 2022-12-16 薬学的眼用組成物およびその使用 Pending JP2024544393A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163290781P 2021-12-17 2021-12-17
US63/290,781 2021-12-17
PCT/US2022/081775 WO2023114986A1 (en) 2021-12-17 2022-12-16 Ophthalmic pharmaceutical compositions and uses thereof

Publications (2)

Publication Number Publication Date
JP2024544393A JP2024544393A (ja) 2024-11-29
JP2024544393A5 true JP2024544393A5 (enExample) 2025-11-10

Family

ID=85157426

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024535940A Pending JP2024544393A (ja) 2021-12-17 2022-12-16 薬学的眼用組成物およびその使用

Country Status (10)

Country Link
US (3) US11850221B2 (enExample)
EP (1) EP4447935A1 (enExample)
JP (1) JP2024544393A (enExample)
KR (1) KR20240121320A (enExample)
CN (1) CN118076340A (enExample)
AU (2) AU2022409839B2 (enExample)
CA (1) CA3242833A1 (enExample)
IL (1) IL313616A (enExample)
MX (1) MX2024007092A (enExample)
WO (1) WO2023114986A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3242833A1 (en) 2021-12-17 2023-06-22 Alcon Inc. OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND THEIR USES
US20250384550A1 (en) * 2023-06-09 2025-12-18 Chung Shan Medical University Reagent and kit for identifying and diagnosis ocular surface disease (osd) and use thereof
US20260027050A1 (en) * 2024-07-23 2026-01-29 Alcon Inc. Acoltremon combinations and uses thereof
WO2026154426A1 (en) * 2025-01-16 2026-07-23 Alcon Inc. Ophthalmic pharmaceutical compositions and uses thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1067684A (ja) 1996-06-17 1998-03-10 Mitsubishi Chem Corp 涙液分泌促進剤
JPH10236972A (ja) 1997-02-28 1998-09-08 Mitsubishi Chem Corp 涙液分泌促進剤
JP3142842B1 (ja) 1999-10-22 2001-03-07 ライオン株式会社 眼科用組成物及びソフトコンタクトレンズへの吸着抑制方法
US6569903B2 (en) 1999-12-07 2003-05-27 Rohto Pharmaceutical Co., Ltd. Ophthalmic compositions
US20020009507A1 (en) 2000-01-19 2002-01-24 Alcon Universal Ltd. Use of polyethoxylated castor oil for the treatment of dry eye
AU2003210663A1 (en) 2002-01-25 2003-09-02 The Regents Of The University Of California Methods of modulating cold sensory perception
US20060084684A1 (en) 2002-05-28 2006-04-20 Altana Pharma Ag Topically applicable pharmaceutical preparation
US6919348B2 (en) 2002-05-02 2005-07-19 Edward T. Wei Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
DE10259619A1 (de) 2002-12-18 2004-07-08 Metagen Pharmaceuticals Gmbh Verwendung einer TRPM8 aktivierenden Substanz zur Tumorbehandlung
CA2530884C (en) 2003-07-02 2016-01-12 Genentech, Inc. Trp-p8 active compounds and therapeutic treatment methods
US20050137166A1 (en) 2003-12-19 2005-06-23 Alcon, Inc. Use of cooling agents to relieve mild ocular irritation and enhance comfort
EP1802600A1 (en) 2004-10-13 2007-07-04 Bayer HealthCare AG Substituted 4-benzyloxy-phenylmethylamide derivatives as cold menthol receptor-1 (cmr-1) antagonits for the treatment of urological disorders
US20060111388A1 (en) 2004-11-19 2006-05-25 University Of North Texas Health Science Center At Fort Worth Phenanthroline and derivatives thereof used to lower intraocular pressure in an affected eye
JP5078254B2 (ja) 2004-12-17 2012-11-21 ロート製薬株式会社 眼科用組成物
GB0504194D0 (en) 2005-03-02 2005-04-06 Givaudan Sa Organic compounds
WO2007017092A1 (en) 2005-08-04 2007-02-15 Bayer Healthcare Ag Substituted 4-benzyloxy-benzoic acid amide derivatives
US7727516B2 (en) 2006-02-28 2010-06-01 The Procter & Gamble Company Reduction of hair growth
CN101405009B (zh) 2006-03-23 2011-04-13 千寿制药株式会社 包含黄原胶和葡萄糖的眼科组合物
US7887859B2 (en) 2006-11-02 2011-02-15 Riolan Technologies, Inc. Methods of treating epiphora
GB2451503B (en) 2007-08-01 2011-10-12 Lrc Products Stimulating gel comprising a cyclic carboxamide coolant
FR2934778B1 (fr) 2008-08-11 2012-09-28 Natura Cosmeticos Sa Compositions d'anti-transpirants et procedes permettant de reduire la transpiration chez les humains
US8653099B2 (en) 2008-08-19 2014-02-18 Janssen Pharmaceutica Cold menthol receptor antagonists
ES2377785B2 (es) * 2010-09-08 2012-09-26 Universidad Miguel Hernández De Elche Composición farmacéutica para el tratamiento del ojo seco.
KR102073258B1 (ko) 2014-04-15 2020-02-04 비쭈리 헬스 사이언스 엘엘씨 통증 완화용 국소 조성물, 제조방법 및 용도
ES2625393A1 (es) 2016-01-19 2017-07-19 Universidad Miguel Hernandez De Elche Compuestos agonistas del receptor trpm8 y sus aplicaciones
US20180252700A1 (en) 2016-10-06 2018-09-06 Ora, Inc. Screening agents in dry eye disease
US20220080048A1 (en) * 2016-10-12 2022-03-17 PS Therapy Ltd Opthalmological compositions and methods of use thereof
CN110996904A (zh) 2017-05-19 2020-04-10 奥古根有限公司 眼用组合物及使用方法
EP3705114A1 (en) 2019-03-06 2020-09-09 Avizorex Pharma, S.L. Ophthalmic composition for treating dry eye and symptoms thereof
WO2021195256A1 (en) 2020-03-24 2021-09-30 Aerie Pharmaceuticals, Inc. Pharmaceutical preparation
CA3242833A1 (en) 2021-12-17 2023-06-22 Alcon Inc. OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND THEIR USES

Similar Documents

Publication Publication Date Title
JP2023002662A5 (enExample)
CA2784492C (en) Non-irritating ophthalmic povidone-iodine compositions
JP2018024689A (ja) 安定なポビドンヨード組成物
JP2011093923A (ja) 点眼剤
JP2012520882A5 (enExample)
JP2003510275A (ja) ロテプレドノールと抗ヒスタミン薬の新規な組み合わせ物
JP5009468B2 (ja) 局所用水性液剤
JP2022532766A5 (enExample)
US20090203614A1 (en) Use of agents that prevent the generation of amyloid-like proteins and/or drusen, and/or use of agents that promote sequestration and/or degradation of, and/or prevent the neurotoxic effects of such proteins in the treatment of macular degeneration
KR20090057400A (ko) 트롬빈 수용체 길항제의 동결건조된 신속 붕해성 경구 제형
JP3131693B2 (ja) 眼疾患を処置するための５―メチル―イソオキサゾール―４―カルボン酸アニリド類または２―ヒドロキシエチリデン―シアノ酢酸アニリド類含有医薬組成物
JP2024512121A5 (enExample)
JP4175801B2 (ja) 消炎鎮痛点眼剤
JP2023531725A5 (enExample)
TW201720445A (zh) 角鯊胺之眼用調配物
TWI250023B (en) Pharmaceutical composition for itch treating agent
KR102444571B1 (ko) 세티리진 및 토코페솔란을 포함하는 안과용 조성물
JP6931257B2 (ja) レバミピドを含有する新規ドライアイ治療用点眼組成物及びその可溶化及び安定化方法
RU2024116293A (ru) Офтальмологические фармацевтические композиции и их применение
MX2023005409A (es) Composicion oftalmatica que contiene levofloxacina y ketorolaco, metodo para su preparacion y uso.
US11497747B2 (en) Compositions and methods for treating lung injuries associated with SARS-CoV-2 infections
JP7149991B2 (ja) 発泡剤を含む抗微生物組成物
JP2025502242A5 (enExample)
CA3169401A1 (en) Xanthan-based ophthalmic topical formulations with a reduced dosage regimen
JP2003201250A (ja) 掻痒治療剤